Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anna Zisman

Internal Medicine Chicago, IL Medical Doctor

NPI 1437317740 CMS profile 1116206

5841 S Maryland Ave, Chicago, IL 60637

Open in the dashboard

General payments

$39,942

34 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Zisman of Chicago, IL is reported in the CMS Open Payments database as having received $39,942 across 34 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25,286 17
2024 General $5,910 3
2020 General $150 1
2019 General $8,597 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Zisman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Anna Zisman were reported at $25,286. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Anna Zisman Internal Medicine median Middle half National median
2019 $8,597 $159 $48–$570 $163
2020 $150 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $5,910 $154 $47–$537 $164
2025 $25,286 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $25,252 16 payments
  2. Retrophin, Inc. $9,747 15 payments
  3. Idorsia Pharmaceuticals US Inc $4,865 1 payment
  4. Novo Nordisk Health Care AG $45 1 payment
  5. Alexion Pharmaceuticals, Inc. $35 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,332 7 payments
  2. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $8,150 5 payments
  3. Consulting Fee $5,586 1 payment
  4. Travel and Lodging $2,036 11 payments
  5. Food and Beverage $838 10 payments
Products named General payments · program years 2019–2025
  1. Rivfloza $17,598 11 payments
  2. (815) Thiola $8,747 14 payments
  3. Tryvio $4,865 1 payment
  4. ULTOMIRIS $35 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

413

Median for Nephrology: 954

Drug cost

$153,086

Median for Nephrology: $127,050

Branded share of claims

16.5%

Median for Nephrology: 17.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Thiola Ec Tiopronin Brand 12 $141,724
Potassium Citrate Er Potassium Citrate Brand 43 $6,249
Potassium Chloride Generic 53 $1,240
Amiloride Hcl Generic 35 $839
Indapamide Generic 48 $798
Chlorthalidone Generic 52 $746
Torsemide Generic 27 $552
Losartan Potassium Generic 36 $292
Amlodipine Besylate Generic 53 $215
Lisinopril Generic 14 $194

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,003 Part D prescribers listed as Nephrology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$44,624

Medicare's payments for the services billed

Medicare patients

229

Average age 70

Services billed

465

117 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 57%
Heart failure 52%
Arthritis 48%
Ischemic heart disease 47%
Atrial fibrillation 32%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

34 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record